Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure
OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are demanded after conventional treatment failure. This was a prospective, single-arm, and si...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-10-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523318301840 |
| _version_ | 1817996989988601856 |
|---|---|
| author | ChuanLiang Cui Li Zhou Bin Lian Lu Si XiNan Sheng ZhiHong Chi Yan Kong Xuan Wang BiXia Tang LiLi Mao SiMing Li Jie Dai XieQiao Yan Xue Bai Jun Guo |
| author_facet | ChuanLiang Cui Li Zhou Bin Lian Lu Si XiNan Sheng ZhiHong Chi Yan Kong Xuan Wang BiXia Tang LiLi Mao SiMing Li Jie Dai XieQiao Yan Xue Bai Jun Guo |
| author_sort | ChuanLiang Cui |
| collection | DOAJ |
| description | OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are demanded after conventional treatment failure. This was a prospective, single-arm, and single-center dose escalation study to investigate the safety and preliminary efficacy of apatinib combined with temozolomide in heavily treated advanced melanoma patients. METHODS: Patients were sequentially admitted to four dose-escalating groups of apatinib and temozolomide (three cases in each group) using a traditional 3 + 3 dose escalation design method. RESULTS: Twelve patients were enrolled between December 2016 and August 2017. Most patients with an acral or mucosal primary origin progressed after immunotherapy or targeted therapy. Dose escalation had been completed without dose-limiting toxicity. Common adverse events included hypertension, hand-foot syndrome, proteinuria, neutropenia, nausea, and fatigue. All adverse events were grade 1 or 2, while the maximum tolerated dose was not reached. Up to January 2018, 1 patient achieved partial response, 9 experienced stable disease, and 2 exhibited progressive disease. The objective response rate and disease control rate were 8.3% and 83%, respectively. CONCLUSIONS: In conclusion, apatinib combined with temozolomide was well tolerated and has demonstrated efficacy in advanced melanoma patients. |
| first_indexed | 2024-04-14T02:31:39Z |
| format | Article |
| id | doaj.art-f4b11f4fb38e431aa0c73bf964e6cfd4 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-04-14T02:31:39Z |
| publishDate | 2018-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-f4b11f4fb38e431aa0c73bf964e6cfd42022-12-22T02:17:40ZengElsevierTranslational Oncology1936-52332018-10-0111511551159Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment FailureChuanLiang Cui0Li Zhou1Bin Lian2Lu Si3XiNan Sheng4ZhiHong Chi5Yan Kong6Xuan Wang7BiXia Tang8LiLi Mao9SiMing Li10Jie Dai11XieQiao Yan12Xue Bai13Jun Guo14Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaAddress all correspondence to: Jun Guo, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China.; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, ChinaOBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are demanded after conventional treatment failure. This was a prospective, single-arm, and single-center dose escalation study to investigate the safety and preliminary efficacy of apatinib combined with temozolomide in heavily treated advanced melanoma patients. METHODS: Patients were sequentially admitted to four dose-escalating groups of apatinib and temozolomide (three cases in each group) using a traditional 3 + 3 dose escalation design method. RESULTS: Twelve patients were enrolled between December 2016 and August 2017. Most patients with an acral or mucosal primary origin progressed after immunotherapy or targeted therapy. Dose escalation had been completed without dose-limiting toxicity. Common adverse events included hypertension, hand-foot syndrome, proteinuria, neutropenia, nausea, and fatigue. All adverse events were grade 1 or 2, while the maximum tolerated dose was not reached. Up to January 2018, 1 patient achieved partial response, 9 experienced stable disease, and 2 exhibited progressive disease. The objective response rate and disease control rate were 8.3% and 83%, respectively. CONCLUSIONS: In conclusion, apatinib combined with temozolomide was well tolerated and has demonstrated efficacy in advanced melanoma patients.http://www.sciencedirect.com/science/article/pii/S1936523318301840 |
| spellingShingle | ChuanLiang Cui Li Zhou Bin Lian Lu Si XiNan Sheng ZhiHong Chi Yan Kong Xuan Wang BiXia Tang LiLi Mao SiMing Li Jie Dai XieQiao Yan Xue Bai Jun Guo Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure Translational Oncology |
| title | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure |
| title_full | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure |
| title_fullStr | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure |
| title_full_unstemmed | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure |
| title_short | Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure |
| title_sort | safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure |
| url | http://www.sciencedirect.com/science/article/pii/S1936523318301840 |
| work_keys_str_mv | AT chuanliangcui safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT lizhou safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT binlian safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT lusi safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT xinansheng safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT zhihongchi safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT yankong safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT xuanwang safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT bixiatang safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT lilimao safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT simingli safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT jiedai safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT xieqiaoyan safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT xuebai safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure AT junguo safetyandefficacyofapatinibcombinedwithtemozolomideinadvancedmelanomapatientsafterconventionaltreatmentfailure |